What Cutia Therapeutics does

Cutia Therapeutics is a China-based, Hong Kong-listed (2439.HK) R&D-driven dermatology platform company founded in 2019 and headquartered in Shanghai with additional offices in Beijing and a manufacturing facility in Wuxi, Jiangsu. The company develops and commercializes therapeutics for skin and scalp diseases, anchored by its proprietary CATAME® technology platform — an integrated system of six sub-platforms (Colloidal-Emulsification-Active Encapsulation, Aerosol, Transdermal Delivery, Actives & Formulation Evaluation, Micro/Nano-Particulates & Self-Assembly, and Ex vivo & Efficacy Evaluation) that supports formulation across multiple dosage forms including creams, sprays, ointments, and aerosol foams. The portfolio includes approved products CU-10201 (topical 4% minocycline foam for inflammatory acne, NMPA-approved November 2024), CU-40102 (topical finasteride spray for androgenetic alopecia, NMPA-approved June 2025 and Hong Kong-approved August 2025), and CU-30101 (lidocaine/tetracaine cream, NMPA-approved May 2026), plus a pipeline spanning CU-20101 (botulinum toxin Type A, Phase III completed), CU-40104 (topical dutasteride), CU-40105 (topical finasteride spray, ANDA accepted), CU-10101 (atopic dermatitis small molecule), CU-20401 (recombinant collagenase for submental fat), and CU-40101 (thyroid hormone receptor agonist).

The company generates revenue primarily through dermatology product sales following its first commercial launches in late October 2025, which contributed over RMB 100 million to a total FY2025 revenue of approximately RMB 336 million. Revenue models span direct product sales and licensing/partnership arrangements, notably the March 2026 partnership with Almirall to market topical finasteride and sarecycline in China. Commercialization operates through a hybrid go-to-market combining HCP/KOL engagement via academic conferences, seminars, and on-site medical trainings for institutional sales to medical institutions, alongside e-commerce platform partnerships for consumer access. Target customers are dual-sided: medical institutions, healthcare professionals, and Key Opinion Leaders on the B2B side, and consumers/patients with dermatology needs (alopecia, acne, atopic dermatitis, aesthetic indications) on the B2C side. Operations are exclusively China-focused with no current international expansion beyond Hong Kong regulatory clearance, and the company is led by Founder/CEO Zhang Lele with functional presidents overseeing R&D (Lei Lei), Regulatory Affairs (Zhang Chunna), Manufacturing/QC (Xu Jingxin), and Supporting Platform (Wu Jiaru).

Name

Cutia Therapeutics

Legal name

Cutia Therapeutics Group Limited

Website

https://cutiatx.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Cutia Therapeutics is a Hong Kong-listed Chinese dermatology platform that develops and commercializes innovative therapeutics for skin and scalp diseases using its proprietary CATAME® formulation technology, serving medical institutions, healthcare professionals, and consumers via direct sales, KOL engagement, and e-commerce channels.

Ownership category

akta.pro rank

Product category

Dermatology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

akta.pro secondary industry

Treatment Skincare (Serums, Actives, Acne & Anti-aging) (CRABAAAB)

Keywords

• Dermatology pharmaceuticals
• Topical therapeutics
• Skin disease treatments
• Alopecia treatments
• Transdermal drug delivery

Headquarters

HQ city

Jingan

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Dermatology Product Sales: Revenue generated from commercialization of dermatology products. Two products entered commercialization in late October 2025, generating over RMB100 million in revenue for the year. Total revenue reached approximately RMB336 million with significant growth in the second half.
2. Partnership-based Product Marketing: Revenue from marketing dermatology treatments including topical finasteride and sarecycline through partnership with Almirall in China.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Cutia Therapeutics is an R&D-driven dermatology platform that develops, manufactures and commercializes innovative topical and injectable therapies for skin and scalp diseases. Its commercialized portfolio includes CU-10201 (topical 4% minocycline foam for inflammatory acne) and CU-40102 (topical finasteride spray for androgenetic alopecia), while the pipeline spans botulinum toxin, lidocaine/tetracaine cream, topical dutasteride and recombinant collagenase. The company also markets dermatology treatments through its partnership with Almirall in China.

Product overview

Cutia Therapeutics is an R&D-driven dermatology platform company focused on developing and commercializing innovative therapies for skin and scalp diseases. The company operates its proprietary CATAME® technology platform, which integrates six sub-platforms (CEAE, ARS, TDD, AFE, MiSA, and EVEE) to support formulation development across multiple dosage forms (creams, sprays, ointments, aerosol foams). The commercialized portfolio includes CU-40102 and CU-10201 (both approved for dermatology indications), while the pipeline spans botulinum toxin products (CU-20101), additional topical dermatology treatments (CU-30101, CU-40104, CU-40105), and novel small molecule/biologic candidates (CU-10101, CU-20401, CU-40101).

Differentiator

Problem solved

Functional benefit

Products and services

• CU-10201 (Topical 4% Minocycline Foam)
• CU-40102 (Topical Finasteride Spray)
• CU-20101 (Botulinum Toxin Type A for Injection)
• CU-30101 (Localized Topical Lidocaine and Tetracaine Cream)
• CU-40104 (Topical Dutasteride Agent)
• CU-40105 (Topical Finasteride Spray)
• CU-20401 (Recombinant Mutant Collagenase)
• CU-10101 (Topical Novel Small Molecule Agent)
• CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment)

Quantifiable outcome

• Total revenue reached approximately RMB336 million in 2025
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• AlmirallcoreChannel Partner/ Reseller/ Distributor · 13 March 2026Almirall is expanding its commercial presence in China through separate partnerships with Cutia and Sinomune to market dermatology treatments including topical finasteride and sarecycline. This partnership allows Almirall to leverage Cutia's local market expertise and product portfolio for commercialization in China.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Evolus: US aesthetic medicine company focused on botulinum toxin Type A (Jeuveau) for glabellar lines. Direct peer to Cutia's CU-20101 botulinum toxin program and comparable in pursuing aesthetic dermatology through injectable neurotoxins.
• Verrica Pharmaceuticals: US clinical-stage dermatology therapeutics company developing topical treatments for skin diseases including molluscum contagiosum and common warts. Direct peer in topical-dermatology drug development with similar R&D-stage profile to Cutia.
• Hugel: South Korea-based biopharmaceutical company with global aesthetics franchise including botulinum toxin (Botulax), fillers, and skincare. Direct peer given its overlapping botulinum toxin product development and aesthetics dermatology portfolio.
• Dermavant Sciences: Clinical-stage dermatology company developing topical therapeutics for psoriasis, atopic dermatitis, and other skin conditions (acquired by Organon in 2024). Direct peer in R&D-stage topical dermatology drug development targeting overlapping indications.
• Almirall: European dermatology-focused pharmaceutical company headquartered in Spain and Cutia's announced channel partner for topical finasteride and sarecycline in China. Directly comparable given its R&D-driven dermatology platform and topical/injectable therapeutic focus.
• Arcutis Biotherapeutics: US-listed dermatology specialty pharma focused on topical formulations for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Direct peer in topical-dermatology drug development using proprietary formulation technology to address similar indications as Cutia.
• Sol-Gel Technologies: Israel-based clinical dermatology company developing topical branded generics and innovative treatments for acne, rosacea, and other skin diseases. Direct peer given its topical formulation platform and pipeline overlap with Cutia's dermatology focus.

Broad incumbents

• Galderma: World's largest pure-play dermatology company, offering prescription, aesthetic, and consumer skin health products across acne, rosacea, psoriasis, and neurotoxins. Comparable to Cutia as a broad incumbent spanning both Rx dermatology and aesthetic indications.
• Leo Pharma: Denmark-based global dermatology specialty pharma with strong franchises in psoriasis, atopic dermatitis, and skin infections. Comparable as a broad incumbent that competes in many of Cutia's targeted indications (acne, AD, alopecia).

Regional players

• Shanghai Fosun Pharmaceutical: Large Chinese pharmaceutical conglomerate with a meaningful dermatology and aesthetic-medicine franchise, including aesthetic injectables. Comparable as a Chinese-headquartered regional player operating in overlapping dermatology and aesthetics indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cutia Therapeutics